Literature DB >> 27056999

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D Hoelzer1, R Bassan2, H Dombret3, A Fielding4, J M Ribera5, C Buske6.   

Abstract

Entities:  

Year:  2016        PMID： 27056999     DOI： 10.1093/annonc/mdw025

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  65 in total

Review 1.  Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.

Authors:  Zaina T Al-Salama
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

2.  Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Yinjun Lou; Yafang Ma; Chenyin Li; Sansan Suo; Hongyan Tong; Wenbin Qian; Wenyuan Mai; Haitao Meng; Wenjuan Yu; Liping Mao; Juyin Wei; Weilei Xu; Jie Jin
Journal:  Front Med       Date:  2017-03-27       Impact factor: 4.592

3.  Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients.

Authors:  Amro M S El-Ghammaz; Mohamed O Azzazi; Nevine Mostafa; Hany M Hegab; Amir A Mahmoud
Journal:  Clin Exp Med       Date:  2020-01-31       Impact factor: 3.984

4.  Navigating the nexus of MRD and novel agents in ALL.

Authors:  Anjali S Advani; Edward A Copelan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  Polo-like kinases and acute leukemia.

Authors:  Oksana Goroshchuk; Iryna Kolosenko; Linda Vidarsdottir; Alireza Azimi; Caroline Palm-Apergi
Journal:  Oncogene       Date:  2018-08-13       Impact factor: 9.867

Review 7.  MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.

Authors:  Manuela Tosi; Orietta Spinelli; Matteo Leoncin; Roberta Cavagna; Chiara Pavoni; Federico Lussana; Tamara Intermesoli; Luca Frison; Giulia Perali; Francesca Carobolante; Piera Viero; Cristina Skert; Alessandro Rambaldi; Renato Bassan
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 8.  The landscape of bispecific T cell engager in cancer treatment.

Authors:  Shujie Zhou; Mingguo Liu; Fei Ren; Xiangjiao Meng; Jinming Yu
Journal:  Biomark Res       Date:  2021-05-26

9.  Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.

Authors:  Matthew Mei; Ni-Chun Tsai; Sally Mokhtari; Monzr M Al Malki; Haris Ali; Amandeep Salhotra; Karamjeet Sandhu; Samer Khaled; Eileen Smith; David Snyder; Guido Marcucci; Stephen J Forman; Vinod Pullarkat; Anthony Stein; Ibrahim Aldoss; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-19       Impact factor: 5.742

10.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.

Authors:  C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.